Antibodies

KRN330 (anti-GPA33) is a monoclonal antibody that targets GPA33, a tumor-associated antigen (TAA) which is overexpressed on the surface of certain tumor cells. It exhibits potential immunostimulatory and antineoplastic activities.Purity&gt95%

KRN330 (anti-GPA33) is a monoclonal antibody that targets GPA33, a tumor-associated antigen (TAA) which is overexpressed on the surface of certain tumor cells. It exhibits potential immunostimulatory and antineoplastic activities.Purity&gt95%

KRN330 (anti-GPA33) is a monoclonal antibody that targets GPA33, a tumor-associated antigen (TAA) which is overexpressed on the surface of certain tumor cells. It exhibits potential immunostimulatory and antineoplastic activities.Purity&gt95%

KRN330 (anti-GPA33) is a monoclonal antibody that targets GPA33, a tumor-associated antigen (TAA) which is overexpressed on the surface of certain tumor cells. It exhibits potential immunostimulatory and antineoplastic activities.Purity&gt95%

Lupartumab (anti-LYPD3) is an anti-LYPD3 (C4.4A) monoclonal antibody that can be used for the synthesis of antibody-drug conjugate BAY 1129980.

Lupartumab (anti-LYPD3) is an anti-LYPD3 (C4.4A) monoclonal antibody that can be used for the synthesis of antibody-drug conjugate BAY 1129980.

Lupartumab (anti-LYPD3) is an anti-LYPD3 (C4.4A) monoclonal antibody that can be used for the synthesis of antibody-drug conjugate BAY 1129980.

Lupartumab (anti-LYPD3) is an anti-LYPD3 (C4.4A) monoclonal antibody that can be used for the synthesis of antibody-drug conjugate BAY 1129980.

MEDI-547 (anti-EphA2) is a fully human IgG1 monoclonal antibody that is used for targeting EphA2. It selectively binds to cells expressing the EphA2 receptor.

MEDI-547 (anti-EphA2) is a fully human IgG1 monoclonal antibody that is used for targeting EphA2. It selectively binds to cells expressing the EphA2 receptor.

MEDI-547 (anti-EphA2) is a fully human IgG1 monoclonal antibody that is used for targeting EphA2. It selectively binds to cells expressing the EphA2 receptor.

MEDI-547 (anti-EphA2) is a fully human IgG1 monoclonal antibody that is used for targeting EphA2. It selectively binds to cells expressing the EphA2 receptor.